Funded Biotechnology Startups in Japan
In Japan’s biotechnology funding list (15 most recent rounds, 2025-09-10 to 2026-08-18), Scohia Pharma’s $443M round on 2026-05-28 is a clear size outlier:…
In Japan’s biotechnology funding list (15 most recent rounds, 2025-09-10 to 2026-08-18), Scohia Pharma’s $443M round on 2026-05-28 is a clear size outlier: it dwarfs the next-largest disclosed amount of $16M from Metagen Therapeutics (2025-09-10), and is also the only disclosed round above $50M. Most disclosed financings cluster in the $1M–$16M band, including multiple mid-single-digit rounds such as Arrowsmith’s $7M (2026-06-22) and Restore Vision’s $8M (2026-04-15).
Geographically, Tokyo concentrates heavily: 7 of the 15 entries list Tokyo, with companies spanning LIFESCAPES ($4M on 2026-06-15), Dioseve ($6M on 2026-06-11), and Restore Vision ($8M on 2026-04-15). Temporally, the year skew is sharp toward 2026 (14 of 15 entries), and disclosed sizes follow that pattern with 11 disclosed rounds versus 4 undisclosed, including the most recent Seed entry Surzen Biotherapeutics (undisclosed) dated 2026-08-18.
Most recent rounds
15 shownRelated listings
Frequently asked
Which recent disclosed round is the clear outlier in Japanese biotech funding, and what’s immediately next to it?
Scohia Pharma’s $443M on 2026-05-28 is the largest disclosed amount and dwarfs the next-largest disclosed round: Metagen Therapeutics at $16M on 2025-09-10.
Do disclosed rounds cluster within a narrower funding range, or are there multiple tiers?
After the $443M outlier, disclosed rounds largely fall below $20M; the $16M–$8M tier includes Metagen Therapeutics ($16M, 2025-09-10), Sonire Therapeutics ($13M, 2026-06-17), Restore Vision ($8M, 2026-04-15), and Arrowsmith ($7M, 2026-06-22). Smaller disclosed entries also appear at $1M–$2M, such as Gel-Coat Biomaterials ($1M, 2026-04-22) and Molmir ($2M, 2026-04-22).
Is there a city concentration in this dataset, and does it align with the largest disclosed deals?
Tokyo appears 7 times, including the $443M outlier Scohia Pharma (2026-05-28) and multiple other disclosed rounds: LIFESCAPES $4M (2026-06-15), Dioseve $6M (2026-06-11), and Restore Vision $8M (2026-04-15). Several non-Tokyo cities also show up once or twice, such as Okinawa (Surzen Biotherapeutics, undisclosed; Think Nature, $2M on 2026-04-01).
How much of the list has disclosed funding amounts versus undisclosed, and where are undisclosed entries concentrated in time?
Disclosed amounts cover 11 of 15 rows, while 4 of 15 are undisclosed (e.g., Surzen Biotherapeutics, undisclosed, 2026-08-18; xCARE, undisclosed, 2026-06-09; and Epsilon Molecular Engineering, undisclosed, 2026-05-28). Undisclosed entries appear within the same 2026-heavy period as disclosed rounds, consistent with 14 of 15 entries occurring in 2026.
What stage labels dominate, and how do the largest disclosed rounds map to stage classifications?
“Series Unknown” is the most common stage label with 8 of 15 entries, followed by Series A (4), Series B (2), and Seed (1). The largest disclosed amount (Scohia Pharma $443M on 2026-05-28) is labeled “Series Unknown,” while other large disclosed rounds include Series Unknown (Sonire Therapeutics $13M on 2026-06-17) and Series B (Restore Vision $8M on 2026-04-15).
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.